Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 1096 · Preserve Access to Affordable Generics and Biosimilars Act ·

Reported by committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

15 U.S.C. § 56 Commencement, defense, intervention and supervision of litigation and appeal by Commission or Attorney General

+4 −2Shown
More for 15 U.S.C. § 56
Read § 56Only this section
3 changes the bill asks for here, 3 carried out
  1. Carried out:

    in subparagraph (D), by striking or after the semicolon;

  2. Carried out:

    by inserting or after the semicolon; and

  3. Carried out:

    by inserting after subparagraph (E) the following:(F) under section 27,.

§ 56(a)Procedure for exercise of authority to litigate or appeal(2)–(3)

Start of § 56 to (a)(2)(B) unchanged ·

(C) to obtain judicial review of a rule prescribed by the Commission, or a cease and desist order issued under section 45 of this title;

(D) under the second paragraph of section 49 of this title (relating to enforcement of a subpena) and under the fourth paragraph of such section (relating to compliance with section 46 of this title);[struck: or]

(E) under section 57b–2a of this title;[inserted: or]

(F) [inserted: under section 27,]

the Commission shall have exclusive authority to commence or defend, and supervise the litigation of, such action and any appeal of such action in its own name by any of its attorneys designated by it for such purpose, unless the Commission authorizes the Attorney General to do so. The Commission shall inform the Attorney General of the exercise of such authority and such exercise shall not preclude the Attorney General from intervening on behalf of the United States in such action and any appeal of such action as may be otherwise provided by law.

(3)

(A) If the Commission makes a written request to the Attorney General, within the 10-day period which begins on the date of the entry of the judgment in any civil action in which the Commission represented itself pursuant to paragraph (1) or (2), to represent itself through any of its attorneys designated by it for such purpose before the Supreme Court in such action, it may do so, if—

Rest of § 56 unchanged ·

21 U.S.C. § 355 New drugs

+1 −1Shown
More for 21 U.S.C. § 355
Read § 355Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 505(j)(5)(D)(i)(V) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(5)(D)(i)(V)) is amended by inserting section 27 of the Federal Trade Commission Act or after that the agreement has violated.

§ 355(j)(5)(D)Forfeiture of 180-day exclusivity period.—(i)–(ii)

Start of § 355 to (j)(5)(D)(i)(III) unchanged ·

(IV) Failure to obtain tentative approval.— The first applicant fails to obtain tentative approval of the application within 30 months after the date on which the application is filed, unless the failure is caused by a change in or a review of the requirements for approval of the application imposed after the date on which the application is filed.

(V) Agreement with another applicant, the listed drug application holder, or a patent owner.— The first applicant enters into an agreement with another applicant under this subsection for the drug, the holder of the application for the listed drug, or an owner of the patent that is the subject of the certification under paragraph (2)(A)(vii)(IV), the Federal Trade Commission or the Attorney General files a complaint, and there is a final decision of the Federal Trade Commission or the court with regard to the complaint from which no appeal (other than a petition to the Supreme Court for a writ of certiorari) has been or can be taken that the agreement has violated [inserted: section 27 of ]the [inserted: Federal Trade Commission Act or the ]antitrust laws (as defined in section 12 of title 15, except that the term includes section 45 of title 15 to the extent that that section applies to unfair methods of competition).

(VI) Expiration of all patents.— All of the patents as to which the applicant submitted a certification qualifying it for the 180-day exclusivity period have expired.

(ii) Forfeiture.— The 180-day exclusivity period described in subparagraph (B)(iv) shall be forfeited by a first applicant if a forfeiture event occurs with respect to that first applicant.

Rest of § 355 unchanged ·

Step through the changes